CBIA Stock Overview
Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Canopus BioPharma Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.00025 |
| 52 Week High | US$0.22 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 25.00% |
| 3 Month Change | 0% |
| 1 Year Change | -99.69% |
| 3 Year Change | -99.86% |
| 5 Year Change | -99.91% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| CBIA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -3.1% |
| 1Y | -99.7% | 11.3% | 20.9% |
Return vs Industry: CBIA underperformed the US Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: CBIA underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| CBIA volatility | |
|---|---|
| CBIA Average Weekly Movement | 61.1% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CBIA's share price has been volatile over the past 3 months.
Volatility Over Time: CBIA's weekly volatility has decreased from 83% to 61% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Patrick Prendergast | n/a |
Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and changed its name in 2007.
Canopus BioPharma Incorporated Fundamentals Summary
| CBIA fundamental statistics | |
|---|---|
| Market cap | US$612.55k |
| Earnings (TTM) | US$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs CBIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBIA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CBIA perform over the long term?
See historical performance and comparison